29 December 2021 - Janssen announced today the submission of a biologics license application to the U.S. FDA seeking approval of teclistamab for the treatment of patients with relapsed or refractory multiple myeloma.
Teclistamab is an investigational, off the shelf, T cell redirecting, bispecific antibody targeting both B-cell maturation antigen and CD3.